National Coverage Analysis (NCA) View Public Comments

Tumor Antigen by Immunoassay CA 125 (Addition of Primary Peritoneal Adenocarcinoma as a Covered Indication)

Public Comments

Commenter Comment Information
Taylor, Robert Date: 09/30/2005
Comment:

In our experience, the usefullness of this test is limited, but when positive can be quite helpful in the management of these pts. Since the numbers of pts with this disease are small, and most of the oncologists in our group would not follow the assay if the initial level was normal, the cost burden to CMS should be limited. We would support the addition of Primary Peritoneal CArcinoma to the indications